Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Author affiliations: Albert Einstein College of Medicine, Bronx, New York, USA (S. Arora, V.S. Hemmige, S.P. Jariwala, Y.A. Puius); Montefiore Medical Center, Bronx (S. Arora, V.S. Hemmige, S.P. Jariwala, Y.A. Puius); HinduHrudaySamrat Balasaheb Thackarey Medical College and Dr. Rustom Narsi Cooper Municipal General Hospital, Mumbai, India (C. Mandke); Netaji Subhash Chandra Bose Medical College, Jabalpur, India (M. Chansoria); Bundelkhand Medical College, Sagar, India (S.K. Rawat); Noble Hospital, Pune, India (A. Dravid); Ventakateshwar Hospital, Delhi (Y. Sethi); HCG Comprehensive Cancer Care Hospital, Bangalore, India (G. Medikeri)

Coronavirus disease (COVID-19)–associated mucormycosis (CAM) is an emerging systemic fungal infection caused by Mucorales species. Reports of CAM are increasing, especially in India, where 187 cases have been described (1). Rapid data collection, which can be accomplished through collaborative online registries, is essential to identifying risk factors for CAM (2). We analyzed characteristics of the first 65 cases logged in the Mycotic Infections in COVID-19 (MUNCO) registry in India.

We solicited registry participation through social media and contacts at hospitals in India. The study was approved by the Institutional Review Board of the Albert Einstein College of Medicine (approval no. 2021-13086) and ethics boards of the author-affiliated hospitals, where applicable. Cases were entered into a REDCap database (3) (https://www.covidmucor.com). CAM diagnosis was based on the judgment of the physician entering the data and not dependent on microbiological, pathologic, or radiographic findings. We had follow-up data for 53 (81.5%) patients; outcomes were defined as full recovery (no residual disease), incomplete recovery (continued treatment at day 42, interrupted treatment, palatal perforation, stroke, or paralysis), vision loss, or death. Because early treatment with orbital exenteration might prevent disease spread to the central nervous system, we did not consider vision loss to be a marker of incomplete recovery. We analyzed data using R (4).

The reported infections were diagnosed during April–June 2021. During this time, the B.1.617.2 lineage (Delta variant) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) dominated the samples sequenced by the Indian SARS-CoV-2 Genomics Consortium, constituting 58% of isolates in April, 88% in May, and 86% in June (5).

Most patients were male (73.8%), and most patients had diabetes (80.0%) (Table). Only 3.1% had been taking long-term corticosteroids. No patients had HIV, cancer, or history of stem cell or solid organ transplant. Among patients with available data, the median age was 56 years, median weight was 64 kg, and median hemoglobin A1c level was 7.80%. The median time between COVID-19 diagnosis and mucormycosis diagnosis was 20 days; patients had a median hospital stay of 11.0 days (Appendix Table). Only 3.1% of patients were fully vaccinated with Covishield (Oxford/AstraZeneca, https://www.astrazeneca.com) or Covaxin (Bhart Biotech, https://www.bharatbiotech.com) at the time of COVID-19 diagnosis.

COVID-19 was treated primarily with corticosteroids, remdesivir, or both. Favipravir, doxycycline, azithromycin, ivermectin, and zinc were also common treatments (Table). No patients were treated with tocilizumab.

Figure

Geographic distribution of coronavirus disease–associated mucormycosis, India, 2021. Sizes of circles indicates number of cases in that area. Use of the map recognized by the government of the United States does not endorse the territorial claims of any specific nation.

Figure. Geographic distribution of coronavirus disease–associated mucormycosis, India, 2021. Sizes of circles indicates number of cases in that area. Use of the map recognized by the government of the United States…

We found that most fungal infections occurred in the sinuses or eyes (Table). Amphotericin B, posaconazole, and surgery were the most common antifungal treatments. Among 53 patients with available follow-up data at 42 days, 17 (32.1%) had an incomplete recovery, 20 (37.8%) had a full recovery, 10 (18.9%) had vision loss, and 6 (11.3%) had died (Figure).

In agreement with previous studies, we found that diabetes and steroid use were major risk factors for CAM (1,6). We also documented frequent use of antibacterial treatments, a documented risk factor for mucormycosis (10), for COVID-19. We found a lower death rate than previously reported (1); widespread awareness of CAM might have contributed to increased reporting, earlier diagnosis, and decreased steroid use for treatment of COVID-19. In total, 57% of patients received zinc supplementation, possibly because pathogenic fungi sequester zinc from host tissues. Zinc chelators inhibit the growth of some virulent fungi (7,8) and enhance the efficacy of antifungal agents against some Mucorales strains in vitro (9).

This proof-of-concept study shows that rapid, real-time data collection using online registries of CAM cases can provide clinical insights into the disease (2). For example, data on these 65 cases were collected in 5 days, enabled by rapid data entry and ease of use. MUNCO is especially useful for physicians in settings where electronic medical records are rarely used and patient follow-up is suboptimal. The major weakness of MUNCO is that pragmatic case definitions are based on the opinions of the clinician entering the data. This study also did not have a control group of non–COVID-19–associated mucormycosis cases, which would enable detection of specific risk factors. By August 2021, we had collected data on 693 cases, which we will soon analyze for additional risk factors associated with poor outcomes. In summary, our results show that online registries are a valuable tool to rapidly provide relevant data for real-time surveillance of emerging infections.

Dr. Arora is an academic hospitalist at Montefiore Medical Center, Bronx, NY, USA. His research interests include coronavirus disease management and outcomes.

Access to REDCap was paid for by the Einstein-Montefiore Institute for Clinical & Translational Research under grant no. UL1TR002556-06 to S.J.

V.S.H. receives support for unrelated work from Merck Sharp & Dohme Corp., which manufactures antifungal medications.

Top

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

Source : CDC Emerging Infectious Diseases Journal

NBS Bank Your Caring Bank